Japanese study to evaluate the utility of eribulin dose and schedule in treatment for advanced breast cancer patients(JUST-STUDY)-additional research on patients enrolled in JUST-STUDY
Phase 2
Completed
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000019137
- Lead Sponsor
- PO Advanced Clinical Reserch Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 88
Inclusion Criteria
Not provided
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method